Skip to main content

Market Overview

AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group

AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of Dsuvia (sufentanil sublingual tablet, SST) 30 mcg for the management of acute pain in an ambulatory surgery center.
  • The primary objective of this study was to determine if SST 30 mcg given before emergence from anesthesia was efficacious in reducing initial post-anesthesia care unit pain scores compared to a control group.
  • Secondary outcomes included opioid use and percentage of patients opioid-free, and time until ready to discharge.
  • Data showed that patients in the SST group required 50% fewer opioids, with significantly more of them opioid-free (36% vs. 8%). Furthermore, SST-treated patients had improved overall benefit of analgesia scores compared to the control group.
  • Limitations of the study include that the SST was not compared to an active comparator as it did not allow for preemptive opioid analgesia in the control group.
  • Also, as the data collection ended at discharge, the authors could not assess any additional analgesic benefit of SST beyond the immediate postoperative period.
  • Price Action: ACRX shares trading 0.93% higher at $1.08 on the last check Thursday.

Related Articles (ACRX)

View Comments and Join the Discussion!

Posted-In: Briefs OpioidsBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at